149 related articles for article (PubMed ID: 36344709)
1. Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients.
Cai J; Jiang Y; Chen F; Wu S; Ren H; Wang P; Wang J; Liu W
Ir J Med Sci; 2023 Aug; 192(4):1785-1791. PubMed ID: 36344709
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor-κB pathway in ankylosing spondylitis.
Cai J; Jiang Y; Chen F; Wu S; Ren H; Wang P; Wang J; Liu W
Immun Inflamm Dis; 2023 May; 11(5):e870. PubMed ID: 37249282
[TBL] [Abstract][Full Text] [Related]
3. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1/2/17 cells, and clinical response of tumor necrosis factor inhibitor.
Deng J; Jiang Y; Luan L; Fu S; Huang M; Dai Z; Liao Y; Guo S; Fu Y
Ir J Med Sci; 2024 Feb; 193(1):165-172. PubMed ID: 37420045
[TBL] [Abstract][Full Text] [Related]
5. Blood HDAC4 Variation Links With Disease Activity and Response to Tumor Necrosis Factor Inhibitor and Regulates CD4+ T Cell Differentiation in Ankylosing Spondylitis.
Dou B; Ma F; Jiang Z; Zhao L
Front Med (Lausanne); 2022; 9():875341. PubMed ID: 35602496
[TBL] [Abstract][Full Text] [Related]
6. Circulating PCSK9 relates to aggravated disease activity, Th17/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients.
Meng Y; Zheng X; Zhang Z; Geng H; Li X
Ir J Med Sci; 2023 Dec; 192(6):3187-3194. PubMed ID: 36826711
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
Li M; Zhou X
Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
[TBL] [Abstract][Full Text] [Related]
8. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
[TBL] [Abstract][Full Text] [Related]
9. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
10. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
[No Abstract] [Full Text] [Related]
11. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway.
Yu M; Tang W; Liang W; Xie B; Gao R; Ding P; Gu X; Wang M; Wen S; Sun P
Int Immunopharmacol; 2023 Nov; 124(Pt B):110962. PubMed ID: 37776771
[TBL] [Abstract][Full Text] [Related]
13. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients.
Zhang Y; Ning C; Zhou H; Yan Y; Liu F; Huang Y
Ir J Med Sci; 2021 May; 190(2):631-638. PubMed ID: 32955700
[TBL] [Abstract][Full Text] [Related]
15. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
16. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
Zhou X; Li M
Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice.
Li S; Cao H; Shen D; Chen C; Xing S; Dou F; Jia Q
J Tradit Chin Med; 2019 Aug; 39(4):524-534. PubMed ID: 32186100
[TBL] [Abstract][Full Text] [Related]
18. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.
Xueyi L; Lina C; Zhenbiao W; Qing H; Qiang L; Zhu P
J Clin Immunol; 2013 Jan; 33(1):151-61. PubMed ID: 22926407
[TBL] [Abstract][Full Text] [Related]
19. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
[TBL] [Abstract][Full Text] [Related]
20. MALT1 regulates Th2 and Th17 differentiation
Wang Q; Wang Y; Liu Q; Chu Y; Mi R; Jiang F; Zhao J; Hu K; Luo R; Feng Y; Lee H; Zhou D; Mi J; Deng R
Front Immunol; 2022; 13():913830. PubMed ID: 35967391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
